TRAVERSA SERGIO (Chief Executive Officer) purchased 91.1% of their position (350K shares) of RELMADA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $174.7K — a major conviction buy. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 5/20/2025ACC: 0001213900-25-046085
DirectorOfficer· Chief Executive Officer
Since Dec 2018
+350K
Net shares
Net buyer
$174.7K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
350K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+172.31K
Price / share
$0.45
Trade value
$77.47K
% of position
44.9%
5/16/2025
384.02K→556.34K
Common Stock
Direct
Shares
+30K
Price / share
$0.50
Trade value
$14.99K
% of position
5.4%
5/19/2025
556.34K→586.34K
Common Stock
Direct
Shares
+147.69K
Price / share
$0.56
Trade value
$82.25K
% of position
25.2%
5/20/2025
586.34K→734.02K
Total
Net shares
+350K
Net value
$174.71K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/16/2025 | P · Purchase | +172.31K | $0.45 | $77.47K | 44.9% | 384.02K | 556.34K |
| Common Stock Direct | 5/19/2025 | P · Purchase | +30K | $0.50 | $14.99K | 5.4% | 556.34K | 586.34K |
| Common Stock Direct | 5/20/2025 | P · Purchase | +147.69K | $0.56 | $82.25K | 25.2% | 586.34K | 734.02K |
| Total | +350K | $174.71K | ||||||
Derivative Transactions0
No derivative transactions reported